Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: NCL

Summary for NCL

Gene information	Gene symbol	NCL
	Ensembl ID	ENSG00000115053
	Entrez ID	4691
	Gene name	nucleolin
	Synonyms	C23\|Nsr1
	Gene type	protein_coding
	UniProtAcc	P19338

Top

Dataset with differentially expressed gene: NCL

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-0.5142	4.05e-12
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.813453	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	0.647688	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.280926	5.74e-21
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.327939	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.254956	1.80e-03
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.267337	6.16e-38
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Progenitors	0.537875	4.77e-02
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.315005	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.448901	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.313	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.361716	2.73e-05
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.35793	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.418077	2.95e-24
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.423415	3.70e-30
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.345549	1.92e-05
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.254971	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.338357	6.34e-04
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.80388	3.16e-22
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.307942	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.411996	2.71e-10
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.885605	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.384948	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.290133	3.20e-02
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	0.321524	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.611179	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.707958	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.462834	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.26397	1.76e-06
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.411457	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.29894	7.11e-05
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.251772	3.38e-05
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.471588	6.31e-44
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.362498	2.04e-16
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.599121	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.674431	0.00e+00
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.305183	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.406676	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.25795	2.72e-15
GSE164897_Vem	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib	NA	Malignant cells	-0.379686	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	0.860017	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.722698	0.00e+00

Top

Expression of NCL in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to NCL

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating NCL

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
NCL	hsa-miR-3148	95.6684	NM_005381
NCL	hsa-miR-8065	94.6692	NM_005381
NCL	hsa-miR-561-3p	93.0498	NM_005381
NCL	hsa-miR-215-3p	91.681	NM_005381
NCL	hsa-miR-760	91.6777	NM_005381
NCL	hsa-miR-616-3p	91.6737	NM_005381
NCL	hsa-miR-1-3p	89.9252	NM_005381
NCL	hsa-miR-4780	88.9401	NM_005381
NCL	hsa-miR-12136	88.2852	NM_005381
NCL	hsa-miR-206	87.8174	NM_005381
NCL	hsa-miR-302d-5p	87.7776	NM_005381
NCL	hsa-miR-302b-5p	87.7776	NM_005381
NCL	hsa-miR-613	86.2198	NM_005381
NCL	hsa-miR-493-5p	85.5954	NM_005381
NCL	hsa-miR-135a-2-3p	84.248	NM_005381
NCL	hsa-miR-135b-3p	84.248	NM_005381
NCL	hsa-miR-3613-3p	83.6574	NM_005381
NCL	hsa-miR-5187-5p	82.8042	NM_005381
NCL	hsa-miR-548t-3p	82.7455	NM_005381
NCL	hsa-miR-548aa	82.7455	NM_005381
NCL	hsa-miR-548ap-3p	82.7455	NM_005381
NCL	hsa-miR-4496	82.6336	NM_005381
NCL	hsa-miR-12124	82.6336	NM_005381
NCL	hsa-miR-548h-3p	81.3641	NM_005381
NCL	hsa-miR-548bb-3p	81.3641	NM_005381
NCL	hsa-miR-548d-3p	81.3641	NM_005381
NCL	hsa-miR-548ac	81.3641	NM_005381
NCL	hsa-miR-548z	81.3641	NM_005381
NCL	hsa-miR-600	81.1305	NM_005381

Page: 1

Top

Motifs and transcription factors (TFs) regulating NCL

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
NCL	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	ETS2 (directAnnotation).
NCL	jaspar__MA0079.5	SP1 (directAnnotation).
NCL	metacluster_174.3	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).
NCL	metacluster_174.2	CEBPZ; CEBPZ; DRAP1; FOS; FOXI1; FOXI1; HMGXB3; IRF3; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYB; NFYB; NFYB; NFYB; NFYB; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; PBX3; PBX3; SP2 (directAnnotation). NFYA; NFYA; NFYC; PBX1; PBX3 (inferredBy_Orthology).
NCL	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	ETV5; HOXA2 (directAnnotation).
NCL	taipale_tf_pairs__ELK1_FOXI1_RSCGGATGTKKN_CAP	ELK1; FOXI1 (directAnnotation).
NCL	metacluster_191.3	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).
NCL	taipale_tf_pairs__ERF_FOXI1_RSCGGATGTTKWN_CAP_repr	ERF; FOXI1 (directAnnotation).
NCL	taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP	ELK3; FOXO1 (directAnnotation).
NCL	transfac_pro__M04950	EGR1 (directAnnotation).
NCL	transfac_pro__M04862	NRF1 (directAnnotation).
NCL	taipale_tf_pairs__ETV2_FOXO6_RCCGGATGTTKWN_CAP	ETV2; FOXO6 (directAnnotation).
NCL	metacluster_22.12	NFE2; NFE2L1 (directAnnotation).
NCL	metacluster_14.28	CLOCK (inferredBy_Orthology).
NCL	metacluster_22.29	NFE2 (directAnnotation).
NCL	metacluster_10.17	ARNT (inferredBy_Orthology).
NCL	homer__NVCACGTG_NPAS	NPAS2 (inferredBy_Orthology).
NCL	cisbp__M05832	MAX (directAnnotation).
NCL	cisbp__M01752	USF2 (inferredBy_Orthology).
NCL	metacluster_22.13	MAFK (inferredBy_Orthology).
NCL	metacluster_10.48	ID2 (inferredBy_Orthology).
NCL	metacluster_14.8	MLX (directAnnotation).
NCL	hocomoco__MXI1_MOUSE.H11MO.1.A	MXI1 (inferredBy_Orthology).
NCL	taipale_cyt_meth__MLX_NCAYGTGN_eDBD_meth	MLX (directAnnotation).
NCL	transfac_pro__M04844	MAX (directAnnotation).
NCL	flyfactorsurvey__Max_Mnt_SANGER_5_FBgn0017578	MAX (inferredBy_Orthology).
NCL	dbtfbs__MLX_HepG2_ENCSR125DAD_merged_N1	MLX (directAnnotation).
NCL	hocomoco__MLX_HUMAN.H11MO.0.D	MLX (directAnnotation).
NCL	metacluster_10.45	MXD3 (directAnnotation).
NCL	transfac_pro__M01116	ARNTL; ARNTL2 (directAnnotation).
NCL	metacluster_10.30	MXI1 (inferredBy_Orthology).
NCL	metacluster_10.46	MAX (inferredBy_Orthology).
NCL	metacluster_14.6	ARNTL; BHLHE40; BHLHE40; CLOCK (directAnnotation). ARNTL; BHLHE41 (inferredBy_Orthology).
NCL	metacluster_30.4	BACH1; BACH1; MAFG; MAFG; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2 (directAnnotation).
NCL	taipale__YY2_DBD_NNCCGCCATNW_repr	YY2 (directAnnotation).
NCL	metacluster_141.4	GLIS2 (directAnnotation).
NCL	metacluster_33.8	BRCA1; CHD2; CHD2; ETS1; NR3C1; ZBED1; ZBED1; ZBED1; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33 (directAnnotation). CHD2; ZBTB33 (inferredBy_Orthology).
NCL	transfac_pro__M06259	ZNF91 (directAnnotation).
NCL	swissregulon__hs__GMEB2	GMEB2 (directAnnotation).
NCL	metacluster_141.9	TAF1; YY1; YY1 (directAnnotation).
NCL	taipale_cyt_meth__ZBTB2_NTTTMCGGTWAN_eDBD	ZBTB2 (directAnnotation).
NCL	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
NCL	metacluster_141.2	E2F2; E2F3 (directAnnotation).
NCL	taipale_tf_pairs__ELK1_TBX21_TNRCACCGGAAGNN_CAP_repr	ELK1; TBX21 (directAnnotation).
NCL	taipale_cyt_meth__CDX2_NRTCGTAAANNN_eDBD_meth	CDX2 (directAnnotation).
NCL	transfac_pro__M06173	ZNF85 (directAnnotation).
NCL	homer__ACAGGATGTGGT_ETS_RUNX	RUNX1 (directAnnotation).
NCL	taipale_tf_pairs__TEAD4_ETV4_RCCGGAAATRCC_CAP	ETV4; TEAD4 (directAnnotation).
NCL	metacluster_141.1	CREB3; E2F5; IRF9; TEAD2; ZNF175; ZNF197; ZNF354B; ZNF584; ZNF589; ZNF592 (directAnnotation).
NCL	taipale_tf_pairs__ELK1_EOMES_TNRCACCGGAAGN_CAP	ELK1; EOMES (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."